Effect of polymorphisms of three genes mediating monoamine signalling on brain morphometry in schizophrenia and healthy subjects

Clinical Psychopharmacology and Neuroscience

Volumn 13, Issue 1, 2015, Pages 68-82

  Vijayakumari, Anupa A ^a   John, John P ^a   Halahalli, Harsha N ^a,b   Paul, Pradip ^a   Thirunavukkarasu, Priyadarshini ^a   Purushottam, Meera ^a   Jain, Sanjeev ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^b NITTE DEEMED TO BE UNIVERSITY   (India)

Author keywords

5 Hydroxy tryptamine 2a; 5 Hydroxy tryptamine transporter linked polymorphic region; Catechol O methyl transferase; Gene polymorphism; Magnetic resonance imaging; Voxel based morphometry

Indexed keywords

MONOAMINE; NEUROLEPTIC AGENT; RISPERIDONE;

5 HYDROXY TRYPTAMINE 2A GENE; ADULT; ARTICLE; BRAIN REGION; BRAIN SIZE; CATECHOL O METHYLTRANSFERASE GENE; CLINICAL ARTICLE; CONTROLLED STUDY; ETHNICITY; FEMALE; FUNCTIONAL MORPHOLOGY; GENE; GENE CLUSTER; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INDIA; INDIAN; MALE; MENTAL PATIENT; MORPHOMETRICS; NATIONAL HEALTH ORGANIZATION; NEUROPATHOLOGY; OUTPATIENT DEPARTMENT; PHENOTYPE; POLYMORPHIC LOCUS; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SEROTONIN TRANSPORTER GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VOXEL BASED MORPHOMETRY;

EID: 84929456798     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2015.13.1.68     Document Type: Article

References (60)

1. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000;157:16-25.
2. Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry 2006;188:510-518.
3. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res 2001;49:1-52.
4. Burke L, Androutsos C, Jogia J, Byrne P, Frangou S. The Maudsley Early Onset Schizophrenia Study: the effect of age of onset and illness duration on fronto-parietal gray matter. Eur Psychiatry 2008;23:233-236.
5. Barnes J, Ridgway GR, Bartlett J, Henley SM, Lehmann M, Hobbs N, et al. Head size, age and gender adjustment in MRI studies: a necessary nuisance? Neuroimage 2010;53:1244-1255.
6. Schwarzkopf SB, Olson SC, Coffman JA, Nasrallah HA. Third and lateral ventricular volumes in schizophrenia: support for progressive enlargement of both structures. Psychopharmacol Bull 1990;26:385-391.
7. Keshavan MS, Bagwell WW, Haas GL, Sweeney JA, Schooler NR, Pettegrew JW. Changes in caudate volume with neuroleptic treatment. Lancet 1994;344:1434.
8. Borne J, Riascos R, Cuellar H, Vargas D, Rojas R. Neuroimaging in drug and substance abuse part II: opioids and solvents. Top Magn Reson Imaging 2005;16:239-245.
9. Bennett CM, Wolford GL, Miller MB. The principled control of false positives in neuroimaging. Soc Cogn Affect Neurosci 2009;4:417-422.
10. Ioannidis JP. Excess significance bias in the literature on brain volume abnormalities. Arch Gen Psychiatry 2011;68:773-780.
11. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005;10:40-68.
12. Girard SL, Dion PA, Rouleau GA. Schizophrenia genetics: putting all the pieces together. Curr Neurol Neurosci Rep 2012;12:261-266.
13. McGuffin P, Owen MJ, Farmer AE. Genetic basis of schizophrenia. Lancet 1995;346:678-682.
14. Camarena B, Fresán A, Aguilar A, Escamilla R, Saracco R, Palacios J, et al. Monoamine oxidase a and B gene polymorphisms and negative and positive symptoms in schizophrenia. ISRN Psychiatry 2012;2012:852949.
15. Wei YL, Li CX, Li SB, Liu Y, Hu L. Association study of monoamine oxidase A/B genes and schizophrenia in Han Chinese. Behav Brain Funct 2011;7:42.
16. Ehrlich S, Morrow EM, Roffman JL, Wallace SR, Naylor M, Bockholt HJ, et al. The COMT Val108/158Met polymorphism and medial temporal lobe volumetry in patients with schizophrenia and healthy adults. Neuroimage 2010;53:992-1000.
17. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996;6:243-250.
18. Shifman S, Bronstein M, Sternfeld M, Pisanté-Shalom A, Lev-Lehman E, Weizman A, et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002;71:1296-1302.
19. Glatt SJ, Faraone SV, Tsuang MT. Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family-based studies. Am J Psychiatry 2003;160:469-476.
20. Voisey J, Swagell CD, Hughes IP, Lawford BR, Young RM, Morris CP. HapMap tag-SNP analysis confirms a role for COMT in schizophrenia risk and reveals a novel association. Eur Psychiatry 2012;27:372-376.
21. Hoenicka J, Garrido E, Martínez I, Ponce G, Aragüés M, Rodríguez-Jiménez R, et al PARGPARG. Gender-specific COMT Val158Met polymorphism association in Spanish schizophrenic patients. Am J Med Genet B Neuropsychiatr Genet 2010;153B:79-85.
22. Gupta M, Bhatnagar P, Grover S, Kaur H, Baghel R, Bhasin Y, et al. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 2009;10:385-397.
23. Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS, et al. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 2008;13:570-584.
24. Apud JA, Weinberger DR. Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors. CNS Drugs 2007;21:535-557.
25. Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS, et al. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 2003;60:889-896.
26. Ohnishi T, Hashimoto R, Mori T, Nemoto K, Moriguchi Y, Iida H, et al. The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia. Brain 2006;129:399-410.
27. Honea R, Verchinski BA, Pezawas L, Kolachana BS, Callicott JH, Mattay VS, et al. Impact of interacting functional variants in COMT on regional gray matter volume in human brain. Neuroimage 2009;45:44-51.
28. Erdmann J, Shimron-Abarbanell D, Rietschel M, Albus M, Maier W, Körner J, et al. Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum Genet 1996;97:614-619.
29. Ni J, Lu W, Wu Z, Chen J, Yi Z, Zhang C. T102C polymorphism of serotonin 2A type receptor gene confers susceptibility to (early onset) schizophrenia in Han Chinese: an association study and meta-analysis. Asia Pac Psychiatry 2013;5:24-30.
30. Tay AH, Lim LC, Lee WL, Wong KE, Wong LY, Tsoi WF. Association between allele 1 of T102C polymorphism, 5-hydroxytryptamine 2a receptor gene and schizophrenia in Chinese males in Singapore. Hum Hered 1997;47:298-300.
31. Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT. Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr Res 2004;67:53-62.
32. Williams J, Spurlock G, McGuffin P, Mallet J, Nöthen MM, Gill M, et al. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group. Lancet 1996;347:1294-1296.
33. Filippini N, Scassellati C, Boccardi M, Pievani M, Testa C, Bocchio-Chiavetto L, et al. Influence of serotonin receptor 2A His452Tyr polymorphism on brain temporal structures: a volumetric MR study. Eur J Hum Genet 2006;14:443-449.
34. Lesch KP, Mössner R. Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Biol Psychiatry 1998;44:179-192.
35. Pae CU, Kim JJ, Lee SJ, Lee CU, Lee C, Paik IH, et al. Polymorphism of the serotonin transporter gene and symptomatic dimensions of schizophrenia in the Korean population. Neuropsychobiology 2003;47:182-186.
36. Golimbet VE, Alfimova MV, Shcherbatikh T, Kaleda VG, Abramova LI, Rogaev EI. Serotonin transporter gene polymorphism and schizoid personality traits in the patients with psychosis and psychiatrically well subjects. World J Biol Psychiatry 2003;4:25-29.
37. Bayle FJ, Leroy S, Gourion D, Millet B, Olié JP, Poirier MF, et al. 5HTTLPR polymorphism in schizophrenic patients: further support for association with violent suicide attempts. Am J Med Genet B Neuropsychiatr Genet 2003;119B:13-17.
38. Park SH, Kim MC, Yoon SH, Kong BG, Kim YH. Association between serotonin transporter polymorphism and the effect of atypical antipsychotics on serum glucose and lipids. Korean J Psychopharmacol 2004;15:196-205.
39. Vijayan NN, Iwayama Y, Koshy LV, Natarajan C, Nair C, Allencherry PM, et al. Evidence of association of serotonin transporter gene polymorphisms with schizophrenia in a South Indian population. J Hum Genet 2009;54:538-542.
40. Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS, et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 2005;8:828-834.
41. Young KA, Holcomb LA, Bonkale WL, Hicks PB, Yazdani U, German DC. 5HTTLPR polymorphism and enlargement of the pulvinar: unlocking the backdoor to the limbic system. Biol Psychiatry 2007;61:813-818.
42. McIntosh AM, Baig BJ, Hall J, Job D, Whalley HC, Lymer GK, et al. Relationship of catechol-O-methyltransferase variants to brain structure and function in a population at high risk of psychosis. Biol Psychiatry 2007;61:1127-1134.
43. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
44. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-667.
45. th ed. London: Informa Healthcare; 2009.
46. Kroken RA, Johnsen E, Ruud T, Wentzel-Larsen T, Jørgensen HA. Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry 2009;9:24.
47. Ashburner J, Friston KJ. Unified segmentation. Neuroimage 2005;26:839-851.
48. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
49. Ruiz-Sanz JI, Aurrekoetxea I, Ruiz del Agua A, Ruiz-Larrea MB. Detection of catechol-O-methyltransferase Val158Met polymorphism by a simple one-step tetra-primer amplification refractory mutation system-PCR. Mol Cell Probes 2007;21:202-207.
50. Wendland JR, Martin BJ, Kruse MR, Lesch KP, Murphy DL. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry 2006;11:224-226.
51. Zinkstok J, Schmitz N, van Amelsvoort T, de Win M, van den Brink W, Baas F, et al. The COMT val158met polymorphism and brain morphometry in healthy young adults. Neurosci Lett 2006;405:34-39.
52. Hranilovic D, Stefulj J, Schwab S, Borrmann-Hassenbach M, Albus M, Jernej B, et al. Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression. Biol Psychiatry 2004;55:1090-1094.
53. McNab F, Leroux G, Strand F, Thorell L, Bergman S, Klingberg T. Common and unique components of inhibition and working memory: an fMRI, within-subjects investigation. Neuropsychologia 2008;46:2668-2682.
54. Shenton ME, Whitford TJ, Kubicki M. Structural neuroimaging in schizophrenia: from methods to insights to treatments. Dialogues Clin Neurosci 2010;12:317-332.
55. Honea R, Crow TJ, Passingham D, Mackay CE. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am J Psychiatry 2005;162:2233-2245.
56. Zhang JP, Malhotra AK. Genetics of schizophrenia: What do we know? Curr Psychiatr 2013;12:24-33.
57. Deng MY, McAlonan GM, Cheung C, Chiu CP, Law CW, Cheung V, et al. A naturalistic study of grey matter volume increase after early treatment in anti-psychotic naïve, newly diagnosed schizophrenia. Psychopharmacology (Berl) 2009;206:437-446.
58. Taylor WD, Züchner S, Payne ME, Messer DF, Doty TJ, MacFall JR, et al. The COMT Val158Met polymorphism and temporal lobe morphometry in healthy adults. Psychiatry Res 2007;155:173-177.
59. Potvin S, Mancini-Marïe A, Fahim C, Mensour B, Lévesque J, Karama S, et al. Increased striatal gray matter densities in patients with schizophrenia and substance use disorder: a voxel-based morphometry study. Psychiatry Res 2007;154:275-279.
60. Dutt A, McDonald C, Dempster E, Prata D, Shaikh M, Williams I, et al. The effect of COMT, BDNF, 5-HTT, NRG1 and DTNBP1 genes on hippocampal and lateral ventricular volume in psychosis. Psychol Med 2009;39:1783-1797.